US 12,343,152 B2
Wearable cardioverter defibrillator having reduced noise prompts
Joseph L. Sullivan, Kirkland, WA (US); and Jaeho Kim, Redmond, WA (US)
Assigned to West Affum Holdings Designated Activity Company, Dublin (IE)
Filed by West Affum Holdings DAC, Dublin (IE)
Filed on Dec. 27, 2023, as Appl. No. 18/397,061.
Application 18/397,061 is a division of application No. 17/487,339, filed on Sep. 28, 2021, granted, now 11,890,098.
Application 17/487,339 is a division of application No. 15/861,463, filed on Jan. 3, 2018, granted, now 11,154,230, issued on Oct. 26, 2021.
Claims priority of provisional application 62/442,919, filed on Jan. 5, 2017.
Prior Publication US 2024/0122518 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/31 (2021.01); A61B 5/00 (2006.01); A61B 5/316 (2021.01); A61N 1/39 (2006.01); A61B 5/333 (2021.01); A61N 1/04 (2006.01)
CPC A61B 5/316 (2021.01) [A61B 5/6805 (2013.01); A61N 1/3904 (2017.08); A61N 1/3925 (2013.01); A61B 5/333 (2021.01); A61N 1/0484 (2013.01); A61N 1/3968 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A wearable cardioverter defibrillator (WCD), comprising:
a support structure configured to be worn by a patient;
an energy storage module configured to store an electrical charge;
a discharge circuit coupled to the energy storage module;
one or more electrodes configured to render an electrocardiogram (ECG) signal of the patient while the patient is wearing the support structure;
a user interface configured to output an alarm in response to a noise alarm signal; and
a processor configured to:
receive the ECG signal,
determine when high amplitude noise is present on the ECG signal, and
suspend ECG analysis when the determined high amplitude noise persists for more than a predetermined amount of time.